Global Challenge of Multidrug-Resistant Acinetobacter baumannii

By F. Pérez, A. Hujer, K. Hujer, Brooke K. Decker, P. Rather, Robert A. Bonomo. Antimicrobial Agents and Chemotherapy, 2007

1,265 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Endocrinology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/b6137df477bf6d9375347cd9ca6ee739cfb3b19f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

In Endocrinology

In Molecular Medicine

Citations in the corpus

A deep learning approach to antibiotic discovery (2020, background): “Of note, the World Health Organization has designated A. baumannii as one of the highest priority pathogens against which new antibiotics are urgently required (Lee et al., 2017; Perez et al., 2007).”
Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options (2017, background): “The OXA23 enzyme was first identified in an A. baumannii isolate in the United Kingdom in 1985 (Perez et al., 2007).”
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges (2016, background): “Acinetobacter also possesses class B -lactamases (metallo- -lactamases [MBLs]) (156).”
An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii (2007, background): “baumannii is attracting much attention owing to the increase in antimicrobial resistance and occurrence of strains that are resistant to virtually all available drug”
A Deep Learning Approach to Antibiotic Discovery. (2020, positive): “baumannii as one of the highest priority pathogens against which new antibiotics are urgently required (Lee et al., 2017; Perez et al., 2007).”
Acinetobacter baumannii: Emergence of a Successful Pathogen (2008, background): “baumannii is impressive and rivals those of other nonfermentative gram-negative pathogens (Table 2) (426, 443).”
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria (2012, background): “The available evidence shows that the proportion of Gram-negative organisms resistant to commonly used antibiotics is increasing (97, 184, 192, 202).”
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “The incidence of infection due to MDR Acinetobacter species continues to increase globally [73, 74].”